Thus, targeting the CXCL13/CXCR5/ERK/TNF-α and IL-1β pathway in the TG may provide a novel therapeutic approach for the treatment of the trigeminal neuralgia. This evidence concerns the gene CXCL13 and trigeminal nerve disorder.